314 related articles for article (PubMed ID: 16752413)
1. Cancer proteomics and its application to discovery of therapy response markers in human cancer.
Smith L; Lind MJ; Welham KJ; Cawkwell L;
Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in clinical oncoproteomics.
Jain KK
J BUON; 2007 Sep; 12 Suppl 1():S31-8. PubMed ID: 17935275
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status.
Hodgkinson VC; Eagle GL; Drew PJ; Lind MJ; Cawkwell L
Cancer Lett; 2010 Aug; 294(1):13-24. PubMed ID: 20176436
[TBL] [Abstract][Full Text] [Related]
4. Oncoproteomics: current trends and future perspectives.
Cho WC; Cheng CH
Expert Rev Proteomics; 2007 Jun; 4(3):401-10. PubMed ID: 17552924
[TBL] [Abstract][Full Text] [Related]
5. Clinical proteomics in breast cancer: a review.
Gast MC; Schellens JH; Beijnen JH
Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
[TBL] [Abstract][Full Text] [Related]
6. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
7. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery.
Hu S; Yen Y; Ann D; Wong DT
Drug Discov Today; 2007 Nov; 12(21-22):911-6. PubMed ID: 17993408
[TBL] [Abstract][Full Text] [Related]
8. Application of proteomics in ovarian cancer: which sample should be used?
Cadron I; Van Gorp T; Timmerman D; Amant F; Waelkens E; Vergote I
Gynecol Oncol; 2009 Dec; 115(3):497-503. PubMed ID: 19811810
[TBL] [Abstract][Full Text] [Related]
9. Oncoproteomics.
Joshi S; Tiwari AK; Mondal B; Sharma A
Clin Chim Acta; 2011 Jan; 412(3-4):217-26. PubMed ID: 20955692
[TBL] [Abstract][Full Text] [Related]
10. Predicting cancer drug response by proteomic profiling.
Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
[TBL] [Abstract][Full Text] [Related]
11. Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials.
Christensen E; Evans KR; Ménard C; Pintilie M; Bristow RG
Cancer Metastasis Rev; 2008 Sep; 27(3):375-85. PubMed ID: 18427732
[TBL] [Abstract][Full Text] [Related]
12. Cancer proteomics.
Tan HT; Lee YH; Chung MC
Mass Spectrom Rev; 2012; 31(5):583-605. PubMed ID: 22422534
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
[TBL] [Abstract][Full Text] [Related]
14. Proteomic approaches in lung cancer biomarker development.
Cho JY; Sung HJ
Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
[TBL] [Abstract][Full Text] [Related]
15. Epithelial proteomics in multiple organs and tissues: similarities and variations between cells, organs, and diseases.
Zhao H; Adler KB; Bai C; Tang F; Wang X
J Proteome Res; 2006 Apr; 5(4):743-55. PubMed ID: 16602680
[TBL] [Abstract][Full Text] [Related]
16. [Proteomics techniques and their application in haemato-oncologic malignancies].
Zelená J; Hájek R
Cas Lek Cesk; 2007; 146(7):586-92. PubMed ID: 17722845
[TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
18. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective.
Matharoo-Ball B; Ball G; Rees R
Vaccine; 2007 Sep; 25 Suppl 2():B110-21. PubMed ID: 17916461
[TBL] [Abstract][Full Text] [Related]
19. Mass spectrometry: uncovering the cancer proteome for diagnostics.
van der Merwe DE; Oikonomopoulou K; Marshall J; Diamandis EP
Adv Cancer Res; 2007; 96():23-50. PubMed ID: 17161675
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer.
Chapal N; Molina L; Molina F; Laplanche M; Pau B; Petit P
Fundam Clin Pharmacol; 2004 Aug; 18(4):413-22. PubMed ID: 15312147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
